Recent Finacing
Recent Raise
Psylo develops non-hallucinogenic neuroplastogens (5‑HT2A agonists) for depression and other mental-health disorders, using AI and computational chemistry to design molecules for safe at‑home administration.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
